Search

Your search keyword '"Löve, A."' showing total 77 results
Start Over Author "Löve, A." Publisher elsevier bv
77 results on '"Löve, A."'

2. Adopting a child perspective for exposome research on mental health and cognitive development - Conceptualisation and opportunities.

Author

Person Waye, Kerstin, primary, Löve, Jesper, additional, Lercher, Peter, additional, Dzhambov, Angel M., additional, Klatte, Maria, additional, Schreckenberg, Dirk, additional, Belke, Christin, additional, Leist, Larisa, additional, Ristovska, Gordana, additional, Jeram, Sonja, additional, Kanninen, Katja M., additional, Selander, Jenny, additional, Arat, Arzu, additional, Lachmann, Thomas, additional, Clark, Charlotte, additional, Botteldooren, Dick, additional, White, Kim, additional, Julvez, Jordi, additional, Foraster, Maria, additional, Kaprio, Jaakko, additional, Bolte, Gabriele, additional, Psyllidis, Achilleas, additional, Gulliver, John, additional, Boshuizen, Hendriek, additional, Bozzon, Alessandro, additional, Fels, Janina, additional, Hornikx, Maarten, additional, van den Hazel, Peter, additional, Weber, Miriam, additional, Brambilla, Marco, additional, Braat-Eggen, Ella, additional, Van Kamp, Irene, additional, and Vincens, Natalia, additional

Published
2023
Full Text
View/download PDF

3. Three years of wastewater surveillance for new psychoactive substances from 16 countries

Author

Bade, Richard, primary, Rousis, Nikolaos, additional, Adhikari, Sangeet, additional, Baduel, Christine, additional, Bijlsma, Lubertus, additional, Bizani, Erasmia, additional, Boogaerts, Tim, additional, Burgard, Daniel A., additional, Castiglioni, Sara, additional, Chappell, Andrew, additional, Covaci, Adrian, additional, Driver, Erin M., additional, Sodre, Fernando Fabriz, additional, Fatta-Kassinos, Despo, additional, Galani, Aikaterini, additional, Gerber, Cobus, additional, Gracia-Lor, Emma, additional, Gracia-Marín, Elisa, additional, Halden, Rolf U., additional, Heath, Ester, additional, Hernandez, Felix, additional, Jaunay, Emma, additional, Lai, Foon Yin, additional, Lee, Heon-Jun, additional, Laimou-Geraniou, Maria, additional, Oh, Jeong-Eun, additional, Olafsdottir, Kristin, additional, Phung, Kaitlyn, additional, Castro, Marco Pineda, additional, Psichoudaki, Magda, additional, Shao, Xueting, additional, Salgueiro-Gonzalez, Noelia, additional, Feitosa, Rafael Silva, additional, Gomes, Cezar Silvino, additional, Subedi, Bikram, additional, Löve, Arndís Sue Ching, additional, Thomaidis, Nikolaos, additional, Tran, Diana, additional, van Nuijs, Alexander, additional, Verovšek, Taja, additional, Wang, Degao, additional, White, Jason M., additional, Yargeau, Viviane, additional, Zuccato, Ettore, additional, and Mueller, Jochen F., additional

Published
2023
Full Text
View/download PDF

4. Sustained low prevalence of HCV viremia among people who inject drugs following the treatment as prevention for hepatitis C (TraP HepC) nationwide elimination program in Iceland

Author

Gottfredsson, Magnús, primary, Runarsdottir, Valgerdur, additional, Löve, Thorvardur J., additional, Fridriksdottir, Ragnheidur H., additional, Tyrfingsson, Thorarinn, additional, Hansdottir, Ingunn, additional, Bergmann, Ottar M., additional, Björnsson, Einar S., additional, Johannsson, Birgir, additional, Sigurdardottir, Bryndis, additional, Löve, Arthur, additional, Baldvinsdóttir, Guðrún Erna, additional, Thordardottir, Marianna, additional, Hernandez, Ubaldo Benitez, additional, Heimisdottir, Maria, additional, and Olafsson, Sigurdur, additional

Published
2022
Full Text
View/download PDF

5. Burden of rotavirus disease in young children in Iceland – Time to vaccinate?

Author

Tinna Laufey Ásgeirsdóttir, Valtyr Thors, Arthur Löve, Iris Kristinsdottir, Ásgeir Haraldsson, Læknadeild (HÍ), Faculty of Medicine (UI), Heilbrigðisvísindasvið (HÍ), School of Health Sciences (UI), Háskóli Íslands, and University of Iceland

Subjects
Rotavirus, medicine.medical_specialty, Pediatrics, Cost effectiveness, Iceland, Börn, medicine.disease_cause, Rotavirus Infections, Epidemiology, medicine, Humans, Iðrakvef, Child, Disease burden, General Veterinary, General Immunology and Microbiology, business.industry, Vaccination, Rotavirus Vaccines, Public Health, Environmental and Occupational Health, Infant, Emergency department, Bólusetningar, Rotavirus vaccine, Infectious Diseases, Immunization, Child, Preschool, Molecular Medicine, business
Abstract

© 2021 Published by Elsevier Ltd., Background: Acute gastroenteritis poses a significant burden on young children, families, health care facilities and societies. Rotavirus is the most common pathogen, but rotavirus infections are vaccine preventable. Information on the epidemiology of gastroenteritis in Icelandic children has until now not been available and rotavirus vaccination is currently not offered to Icelandic infants. The objective of this study was to assess the burden of rotavirus acute gastroenteritis in young children in Iceland and determine the potential benefit of adding rotavirus vaccine to the Icelandic childhood immunization schedule. Methods: For a two-year period, children < 6 years old attending a children’s emergency department for acute gastroenteritis were recruited at the Children’s Hospital in Reykjavík, Iceland. Demographic information and Vesikari scores were registered. Stool samples were analyzed for pathogens. Duration of symptoms, treatment given, and secondary household infections were among the collected information. Annual cost of the infections in young children was estimated based on health care expenditures and lost days of parental work. Results: 325 children were included in the study, 75% of which were 24 months old. A pathogen was identified in 80% of cases, of which rotavirus was identified in 54%. Rotavirus caused a more severe disease than other pathogens, more often leading to fluid treatment in the emergency department and admissions. Median duration of rotavirus-illness was six days and caused a median of four days lost from work by parents. The estimated annual cost of rotavirus acute gastroenteritis was €2.9 million. Conclusions: Rotavirus causes significant disease burden in young children. Although rarely lifethreatening in high income countries, the costs for society are substantial. The inclusion of rotavirus vaccine in the national immunization schedule will reduce the disease burden and would be cost-saving in Iceland., RANNÍS

Published
2021
Full Text
View/download PDF

6. Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based study

Author

Bryndis Sigurdardottir, Magnus Gottfredsson, Arthur Löve, Ottar M. Bergmann, Ragnheidur H Fridriksdottir, Margaret Hellard, Ubaldo Benitez Hernandez, Gudrun E Baldvinsdottir, Sigurdur Olafsson, Thorolfur Gudnason, Maria Heimisdottir, Thorvardur Jon Love, Valgerdur Runarsdottir, Thorarinn Tyrfingsson, Ingunn Hansdottir, Einar S. Bjornsson, and Birgir Johannsson

Subjects
Male, medicine.medical_specialty, Pediatrics, Population, Iceland, Hepacivirus, Antiviral Agents, 03 medical and health sciences, 0302 clinical medicine, Global health, Humans, Medicine, education, Aged, Retrospective Studies, education.field_of_study, Harm reduction, Hepatology, business.industry, Incidence, Public health, Incidence (epidemiology), Gastroenterology, Retrospective cohort study, Hepatitis C, Middle Aged, Treatment as prevention, medicine.disease, Population Surveillance, 030220 oncology & carcinogenesis, DNA, Viral, Female, 030211 gastroenterology & hepatology, Public Health, business, Delivery of Health Care, Follow-Up Studies
Abstract

Summary Background WHO has set targets to eliminate hepatitis C virus (HCV) infection as a global health threat by 2030 through a 65% reduction in HCV-related deaths and 80% reduction in HCV incidence. To achieve these goals, WHO set service coverage targets of 90% of the infected population being diagnosed and 80% of eligible patients being treated. In February, 2016, Iceland initiated a nationwide HCV elimination programme known as treatment as prevention for hepatitis C (TraP HepC), which aimed to maximise diagnosis and treatment access. This analysis reports on the HCV cascade of care in the first 3 years of the programme. Methods This population-based study was done between Feb 10, 2016, and Feb 10, 2019. Participants aged 18 years or older with permanent residence in Iceland and PCR-confirmed HCV were offered direct-acting antiviral (DAA) therapy. The programme used a multidisciplinary team approach in which people who inject drugs were prioritised. Nationwide awareness campaigns, improved access to testing, and harm reduction services were scaled up simultaneously. The number of infected people in the national HCV registry was used in combination with multiple other data sources, including screening of low-risk groups and high-risk groups, to estimate the total number of HCV infections. The number of people diagnosed, linked to care, initiated on treatment, and cured were recorded during the study. This study is registered with ClinicalTrials.gov, NCT02647879. Findings In February, 2016, at the onset of the programme, 760 (95% CI 690–851) individuals were estimated to have HCV infection, with 75 (95% CI 6–166) individuals undiagnosed. 682 individuals were confirmed to be HCV PCR positive. Over the next 3 years, 183 new infections (including 42 reinfections) were diagnosed, for a total of 865 infections in 823 individuals. It was estimated that more than 90% of all domestic HCV infections had been diagnosed as early as January, 2017. During the 3 years, 824 (95·3%) of diagnosed infections were linked to care, and treatment was initiated for 795 (96·5%) of infections linked to care. Cure was achieved for 717 (90·2%) of 795 infections. Interpretation By using a multidisciplinary public health approach, involving tight integration with addiction treatment services, the core service coverage targets for 2030 set by WHO have been reached. These achievements position Iceland to be among the first nations to subsequently achieve the WHO goal of eliminating HCV as a public health threat. Funding The Icelandic Government and Gilead Sciences.

Published
2021
Full Text
View/download PDF

7. OAB-037: Detection of abnormal plasma cells by multiparameter flow cytometry in a screened cohort of patients with monoclonal gammopathy of undetermined significance

Author

Óskarsson, Jón Þórir, primary, Rögnvaldsson, Sæmundur, additional, Þorsteinsdóttir, Sigrún, additional, Pétursdóttir, Íris, additional, Þórðardóttir, Hrafnhildur Una, additional, Gunnarsson, Steinar Bragi, additional, Hákonardóttir, Guðlaug Katrín, additional, Sigurðardóttir, Guðrún Ásta, additional, Þórðardóttir, Ásdís Rósa, additional, Gíslason, Gauti Kjartan, additional, Ólafsson, Andri, additional, Sigurðsson, Jón Kristinn, additional, Viðarsson, Brynjar, additional, Önundarson, Páll Torfi, additional, Agnarsson, Bjarni A., additional, Pálmason, Róbert, additional, Sigurðardóttir, Margrét, additional, Þorsteinsdóttir, Ingunn, additional, Ólafsson, Ísleifur, additional, Durie, Brian, additional, Löve, Þorvarður Jón, additional, and Kristinsson, Sigurður Yngvi, additional

Published
2022
Full Text
View/download PDF

8. Predominance of influenza virus A(H3N2) 3C.2a1b and A(H1N1)pdm09 6B.1A5A genetic subclades in the WHO European Region, 2018–2019

Author

Melidou, Angeliki, Hungnes, Olav, Pereyaslov, Dmitriy, Adlhoch, Cornelia, Segaloff, Hannah, Robesyn, Emmanuel, Penttinen, Pasi, Olsen, Sonja J., Redlberger-Fritz, Monika, Popow-Kraupp, Therese, Hasibra, Iris, Simaku, Artan, Thomas, Isabelle, Barbezange, Cyril, Dedeić-Ljubović, Amela, Rodić-Vukmir, Nina, Korsun, Neli, Angenova, Svetla, Draženović, Vladimir, Koliou, Maria, Pieridou, Despo, Havlickova, Martina, Nagy, Alexander, Trebbien, Ramona, Galiano, Monica, Thompson, Catherine, Ikonen, Niina, Haveri, Anu, Behillil, Sylvie, Enouf, Vincent, Valette, Martine, Lina, Bruno, Gavashelidze, Mari, Machablishvili, Ann, Gioula, Georgia, Exindari, Maria, Kossyvakis, Athanasios, Mentis, Andreas, Dürrwald, Ralf, Zsuzsanna, Molnar, Monika, Rozsa, Löve, Arthur, Erna, Gudrun, Dunford, Linda, Fitzpatrick, Sarah, Castrucci, Maria Rita, Puzelli, Simona, Sagymbay, Altynay, Nussupbayeva, Gaukhar, Zamjatina, Natalija, Pakarna, Gatis, Griskevičius, Algirdas, Skrickiene, Asta, Fournier, Guillaume, Mossong, Joel, Melillo, Jackie, Zahra, Graziella, Meijer, Adam, Fouchier, Ron, McCaughey, Conall, O'Doherty, Mark, Bragstad, Karoline, Guiomar, Raquel, Pechirra, Pedro, Apostol, Mariana, Alina, Druc, Lazar, Mihaela, Maria, Cherciu Carmen, Komissarov, Andrey, Burtseva, Elena, Gunson, Rory N., Shepherd, Samantha, Tichá, Elena, Staronova, Edita, Prosenc, Katarina, Berginc, Nataša, Pozo, Francisco, Casas, Inmaculada, Brytting, Mia, Wiman, Åsa, Gonçalves, Ana Rita, Demchyshyna, Iryna, Mironenko, Alla, Moore, Catherine, Cottrell, Simon, and European Region influenza surveillance network

Subjects
Influenzavirus A, Infecções Respiratórias, viruses, 030231 tropical medicine, Hemagglutinin Glycoproteins, Influenza Virus, Biology, World Health Organization, Virus, Antigenic, 03 medical and health sciences, Influenza A Virus, H1N1 Subtype, 0302 clinical medicine, Vaccine strain, Genetic, Antigen, Influenza, Human, Humans, 030212 general & internal medicine, Clade, Phylogeny, chemistry.chemical_classification, Surveillance, General Veterinary, General Immunology and Microbiology, Influenza A Virus, H3N2 Subtype, Public Health, Environmental and Occupational Health, Subclade, European region, Virology, A h1n1 pdm09, Influenza, Amino acid, Europe, Infectious Diseases, chemistry, Influenza Vaccines, RNA, Viral, Molecular Medicine, Vaccine
Abstract

Network authors: Portugal - Raquel Guiomar, Pedro Pechirra, National Influenza Reference Laboratory, Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge, Lisbon, Portugal Background: The 2018/2019 influenza season in the WHO European Region was dominated by influenza A (H1N1)pdm09 and (H3N2) viruses, with very few influenza B viruses detected. Methods: Countries in the European Region reported virus characterization data to The European Surveillance System for weeks 40/2018 to 20/2019. These virus antigenic and genetic characterization and haemagglutinin (HA) sequence data were analysed to describe and assess circulating viruses relative to the 2018/2019 vaccine virus components for the northern hemisphere. Results: Thirty countries reported 4776 viruses characterized genetically and 3311 viruses antigenically. All genetically characterized A(H1N1)pdm09 viruses fell in subclade 6B.1A, of which 90% carried the amino acid substitution S183P in the HA gene. Antigenic data indicated that circulating A(H1N1)pdm09 viruses were similar to the 2018/2019 vaccine virus. Genetic data showed that A(H3N2) viruses mostly fell in clade 3C.2a (75%) and 90% of which were subclade 3C.2a1b. A lower proportion fell in clade 3C.3a (23%) and were antigenically distinct from the vaccine virus. All B/Victoria viruses belonged to clade 1A; 30% carried a double amino acid deletion in HA and were genetically and antigenically similar to the vaccine virus component, while 55% carried a triple amino acid deletion or no deletion in HA; these were antigenically distinct from each other and from the vaccine component. All B/Yamagata viruses belonged to clade 3 and were antigenically similar to the virus component in the quadrivalent vaccine for 2018/2019. Conclusions: A simultaneous circulation of genetically and antigenically diverse A(H3N2) and B/Victoria viruses was observed and represented a challenge to vaccine strain selection. Highlights: Co-circulation of different clades/subclades of influenza A viruses in 2018/2019 in the Region; Most circulating A(H1N1)pdm09 viruses (6B.1A) carried S183P in hemagglutinin; Genetically heterogeneous A(H3N2) viruses, with co-circulation of clades 3C.2a and 3C.3a; Antigenically distinct A(H3N2) clade 3C.3a viruses were increasingly detected until 02/2019 and then decreased; Co-circulation of genetically and antigenically diverse A(H3N2) strains challenges vaccine strain selection. info:eu-repo/semantics/publishedVersion

Published
2020
Full Text
View/download PDF

9. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

Author

Blach, Sarah, primary, Terrault, Norah A, additional, Tacke, Frank, additional, Gamkrelidze, Ivane, additional, Craxi, Antonio, additional, Tanaka, Junko, additional, Waked, Imam, additional, Dore, Gregory J, additional, Abbas, Zaigham, additional, Abdallah, Ayat R, additional, Abdulla, Maheeba, additional, Aghemo, Alessio, additional, Aho, Inka, additional, Akarca, Ulus S, additional, Alalwan, Abduljaleel M, additional, Alanko Blomé, Marianne, additional, Al-Busafi, Said A, additional, Aleman, Soo, additional, Alghamdi, Abdullah S, additional, Al-Hamoudi, Waleed K, additional, Aljumah, Abdulrahman A, additional, Al-Naamani, Khalid, additional, Al Serkal, Yousif M, additional, Altraif, Ibrahim H, additional, Anand, Anil C, additional, Anderson, Motswedi, additional, Andersson, Monique I, additional, Athanasakis, Kostas, additional, Baatarkhuu, Oidov, additional, Bakieva, Shokhista R, additional, Ben-Ari, Ziv, additional, Bessone, Fernando, additional, Biondi, Mia J, additional, Bizri, Abdul Rahman N, additional, Brandão-Mello, Carlos E, additional, Brigida, Krestina, additional, Brown, Kimberly A, additional, Brown, Jr, Robert S, additional, Bruggmann, Philip, additional, Brunetto, Maurizia R, additional, Busschots, Dana, additional, Buti, Maria, additional, Butsashvili, Maia, additional, Cabezas, Joaquin, additional, Chae, Chungman, additional, Chaloska Ivanova, Viktorija, additional, Chan, Henry Lik Yuen, additional, Cheinquer, Hugo, additional, Cheng, Kent Jason, additional, Cheon, Myeong-Eun, additional, Chien, Cheng-Hung, additional, Chien, Rong-Nan, additional, Choudhuri, Gourdas, additional, Christensen, Peer Brehm, additional, Chuang, Wan-Long, additional, Chulanov, Vladimir, additional, Cisneros, Laura E, additional, Coco, Barbara, additional, Contreras, Fernando A, additional, Cornberg, Markus, additional, Cramp, Matthew E, additional, Crespo, Javier, additional, Cui, Fuqiang, additional, Cunningham, Chris W, additional, Dagher Abou, Lucy, additional, Dalgard, Olav, additional, Dao, Doan Y, additional, De Ledinghen, Victor, additional, Derbala, Moutaz F, additional, Deuba, Keshab, additional, Dhindsa, Karan, additional, Djauzi, Samsuridjal, additional, Drazilova, Sylvia, additional, Duberg, Ann-Sofi, additional, Elbadri, Mohammed, additional, El-Sayed, Manal H, additional, Esmat, Gamal, additional, Estes, Chris, additional, Ezzat, Sameera, additional, Färkkilä, Martti A, additional, Ferradini, Laurent, additional, Ferraz, Maria Lucia G, additional, Ferreira, Paulo R A, additional, Filipec Kanizaj, Tajana, additional, Flisiak, Robert, additional, Frankova, Sona, additional, Fung, James, additional, Gamkrelidze, Amiran, additional, Gane, Edward, additional, Garcia, Virginia, additional, García-Samaniego, Javier, additional, Gemilyan, Manik, additional, Genov, Jordan, additional, Gheorghe, Liliana S, additional, Gholam, Pierre M, additional, Goldis, Adrian, additional, Gottfredsson, Magnus, additional, Gray, Richard T, additional, Grebely, Jason, additional, Gschwantler, Michael, additional, Hajarizadeh, Behzad, additional, Hamid, Saeed S, additional, Hamoudi, Waseem, additional, Hatzakis, Angelos, additional, Hellard, Margaret E, additional, Himatt, Sayed, additional, Hofer, Harald, additional, Hrstic, Irena, additional, Hunyady, Bela, additional, Husa, Petr, additional, Husic-Selimovic, Azra, additional, Jafri, Wasim S M, additional, Janicko, Martin, additional, Janjua, Naveed, additional, Jarcuska, Peter, additional, Jaroszewicz, Jerzy, additional, Jerkeman, Anna, additional, Jeruma, Agita, additional, Jia, Jidong, additional, Jonasson, Jon G, additional, Kåberg, Martin, additional, Kaita, Kelly D E, additional, Kaliaskarova, Kulpash S, additional, Kao, Jia-Horng, additional, Kasymov, Omor T, additional, Kelly-Hanku, Angela, additional, Khamis, Faryal, additional, Khamis, Jawad, additional, Khan, Aamir G, additional, Khandu, Lekey, additional, Khoudri, Ibtissam, additional, Kielland, Knut B, additional, Kim, Do Young, additional, Kodjoh, Nicolas, additional, Kondili, Loreta A, additional, Krajden, Mel, additional, Krarup, Henrik Bygum, additional, Kristian, Pavol, additional, Kwon, Jisoo A, additional, Lagging, Martin, additional, Laleman, Wim, additional, Lao, Wai Cheung, additional, Lavanchy, Daniel, additional, Lázaro, Pablo, additional, Lazarus, Jeffrey V, additional, Lee, Alice U, additional, Lee, Mei-Hsuan, additional, Li, Michael K K, additional, Liakina, Valentina, additional, Lim, Young-Suk, additional, Löve, Arthur, additional, Lukšić, Boris, additional, Machekera, Shepherd Mufudzi, additional, Malu, Abraham O, additional, Marinho, Rui T, additional, Maticic, Mojca, additional, Mekonnen, Hailemichael D, additional, Mendes-Correa, Maria Cássia, additional, Mendez-Sanchez, Nahum, additional, Merat, Shahin, additional, Meshesha, Berhane Redae, additional, Midgard, Håvard, additional, Mills, Mike, additional, Mohamed, Rosmawati, additional, Mooneyhan, Ellen, additional, Moreno, Christophe, additional, Muljono, David H, additional, Müllhaupt, Beat, additional, Musabaev, Erkin, additional, Muyldermans, Gaëtan, additional, Nartey, Yvonne Ayerki, additional, Naveira, Marcelo C M, additional, Negro, Francesco, additional, Nersesov, Alexander V, additional, Njouom, Richard, additional, Ntagirabiri, Rénovat, additional, Nurmatov, Zuridin S, additional, Obekpa, Solomon A, additional, Oguche, Stephen, additional, Olafsson, Sigurdur, additional, Ong, Janus P, additional, Opare-Sem, Ohene K, additional, Orrego, Mauricio, additional, Øvrehus, Anne L, additional, Pan, Calvin Q, additional, Papatheodoridis, George V, additional, Peck-Radosavljevic, Markus, additional, Pessoa, Mário G, additional, Phillips, Richard O, additional, Pimenov, Nikolay, additional, Plaseska-Karanfilska, Dijana, additional, Prabdial-Sing, Nishi N, additional, Puri, Pankaj, additional, Qureshi, Huma, additional, Rahman, Aninda, additional, Ramji, Alnoor, additional, Razavi-Shearer, Devin M, additional, Razavi-Shearer, Kathryn, additional, Ridruejo, Ezequiel, additional, Ríos-Hincapié, Cielo Y, additional, Rizvi, S M Shahriar, additional, Robaeys, Geert K M M, additional, Roberts, Lewis R, additional, Roberts, Stuart K, additional, Ryder, Stephen D, additional, Sadirova, Shakhlo, additional, Saeed, Umar, additional, Safadi, Rifaat, additional, Sagalova, Olga, additional, Said, Sanaa S, additional, Salupere, Riina, additional, Sanai, Faisal M, additional, Sanchez-Avila, Juan F, additional, Saraswat, Vivek A, additional, Sarrazin, Christoph, additional, Sarybayeva, Gulya, additional, Seguin-Devaux, Carole, additional, Sharara, Ala I, additional, Sheikh, Mahdi, additional, Shewaye, Abate B, additional, Sievert, William, additional, Simojoki, Kaarlo, additional, Simonova, Marieta Y, additional, Sonderup, Mark W, additional, Spearman, C Wendy, additional, Sperl, Jan, additional, Stauber, Rudolf E, additional, Stedman, Catherine A M, additional, Su, Tung-Hung, additional, Suleiman, Anita, additional, Sypsa, Vana, additional, Tamayo Antabak, Natalia, additional, Tan, Soek-Siam, additional, Tergast, Tammo L, additional, Thurairajah, Prem H, additional, Tolmane, Ieva, additional, Tomasiewicz, Krzysztof, additional, Tsereteli, Maia, additional, Uzochukwu, Benjamin S C, additional, Van De Vijver, David A M C, additional, Van Santen, Daniela K, additional, Van Vlierberghe, Hans, additional, Van Welzen, Berend, additional, Vanwolleghem, Thomas, additional, Vélez-Möller, Patricia, additional, Villamil, Federico, additional, Vince, Adriana, additional, Waheed, Yasir, additional, Weis, Nina, additional, Wong, Vincent W-S, additional, Yaghi, Cesar G, additional, Yesmembetov, Kakharman, additional, Yosry, Ayman, additional, Yuen, Man-Fung, additional, Yunihastuti, Evy, additional, Zeuzem, Stefan, additional, Zuckerman, Eli, additional, and Razavi, Homie A, additional

Published
2022
Full Text
View/download PDF

10. Sustained low prevalence of HCV viremia among people who inject drugs following the treatment as prevention for hepatitis C (TraP HepC) nationwide elimination program in Iceland

Author

Magnús Gottfredsson, Valgerdur Runarsdottir, Thorvardur J. Löve, Ragnheidur H. Fridriksdottir, Thorarinn Tyrfingsson, Ingunn Hansdottir, Ottar M. Bergmann, Einar S. Björnsson, Birgir Johannsson, Bryndis Sigurdardottir, Arthur Löve, Guðrún Erna Baldvinsdóttir, Marianna Thordardottir, Ubaldo Benitez Hernandez, Maria Heimisdottir, and Sigurdur Olafsson

Subjects
Hepatology
Published
2022
Full Text
View/download PDF

12. No restrictions should be placed on future treatment for patients who discontinue DAAs on their first or second attempt. A real world experience from the TraP HepC initiative in Iceland

Author

Olafsson, Sigurdur, primary, Löve, Thorvardur J., additional, Fridriksdottir, Ragnheidur H., additional, Tyrfingsson, Thorarinn, additional, Runarsdottir, Valgerdur, additional, Hansdottir, Ingunn, additional, Bergmann, Ottar M., additional, Björnsson, Einar S., additional, Johannsson, Birgir, additional, Sigurdardottir, Bryndis, additional, Löve, Arthur, additional, Baldvinsdóttir, Guðrún Erna, additional, Sigmundsdottir, Gudrun, additional, Hernandez, Ubaldo Benitez, additional, Heimisdottir, Maria, additional, and Gottfredsson, Magnús, additional

Published
2020
Full Text
View/download PDF

14. OAB-037: Detection of abnormal plasma cells by multiparameter flow cytometry in a screened cohort of patients with monoclonal gammopathy of undetermined significance

Author

Jón Þórir Óskarsson, Sæmundur Rögnvaldsson, Sigrún Þorsteinsdóttir, Íris Pétursdóttir, Hrafnhildur Una Þórðardóttir, Steinar Bragi Gunnarsson, Guðlaug Katrín Hákonardóttir, Guðrún Ásta Sigurðardóttir, Ásdís Rósa Þórðardóttir, Gauti Kjartan Gíslason, Andri Ólafsson, Jón Kristinn Sigurðsson, Brynjar Viðarsson, Páll Torfi Önundarson, Bjarni A. Agnarsson, Róbert Pálmason, Margrét Sigurðardóttir, Ingunn Þorsteinsdóttir, Ísleifur Ólafsson, Brian Durie, Þorvarður Jón Löve, and Sigurður Yngvi Kristinsson

Subjects
Cancer Research, Oncology, Hematology
Published
2022
Full Text
View/download PDF

16. Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based study

Author

Olafsson, Sigurdur, primary, Fridriksdottir, Ragnheidur H, additional, Love, Thorvardur J, additional, Tyrfingsson, Thorarinn, additional, Runarsdottir, Valgerdur, additional, Hansdottir, Ingunn, additional, Bergmann, Ottar M, additional, Björnsson, Einar S, additional, Johannsson, Birgir, additional, Sigurdardottir, Bryndis, additional, Löve, Arthur, additional, Baldvinsdottir, Gudrun E, additional, Hernandez, Ubaldo Benitez, additional, Gudnason, Thorolfur, additional, Heimisdottir, Maria, additional, Hellard, Margaret, additional, and Gottfredsson, Magnus, additional

Published
2021
Full Text
View/download PDF

18. No restrictions should be placed on future treatment for patients who discontinue DAAs on their first or second attempt. A real world experience from the TraP HepC initiative in Iceland

Author

Sigurdur Olafsson, Thorvardur J. Löve, Ragnheidur H. Fridriksdottir, Thorarinn Tyrfingsson, Valgerdur Runarsdottir, Ingunn Hansdottir, Ottar M. Bergmann, Einar S. Björnsson, Birgir Johannsson, Bryndis Sigurdardottir, Arthur Löve, Guðrún Erna Baldvinsdóttir, Gudrun Sigmundsdottir, Ubaldo Benitez Hernandez, Maria Heimisdottir, and Magnús Gottfredsson

Subjects
Hepatology
Published
2020
Full Text
View/download PDF

19. Aseptic meningitis outbreak associated with echovirus 4 in Northern Europe in 2013–2014

Author

Smura, Teemu, primary, Blomqvist, Soile, additional, Kolehmainen, Pekka, additional, Schuffenecker, Isabelle, additional, Lina, Bruno, additional, Böttcher, Sindy, additional, Diedrich, Sabine, additional, Löve, Arthur, additional, Brytting, Mia, additional, Hauzenberger, Elenor, additional, Dudman, Susanne, additional, Ivanova, Olga, additional, Lukasev, Alexander, additional, Fischer, Thea Kølsen, additional, Midgley, Sofie, additional, Susi, Petri, additional, Savolainen-Kopra, Carita, additional, Lappalainen, Maija, additional, and Jääskeläinen, Anne J., additional

Published
2020
Full Text
View/download PDF

20. Molecular epidemiology of HIV-1 in Iceland: Early introductions, transmission dynamics and recent outbreaks among injection drug users

Author

Guðrún Erna Baldvinsdóttir, Patrik Medstrand, Joakim Esbjörnsson, Anders Widell, Thora Björg Björnsdottir, Hlynur Indriðason, Malik Sallam, Magnús Gottfreðsson, and Arthur Löve

Subjects
Male, 0301 basic medicine, Iceland, HIV Infections, Disease Outbreaks, Men who have sex with men, Drug Users, Risk Factors, Genotype, Prevalence, Cluster Analysis, Phylogeny, Molecular Epidemiology, Phylogenetic tree, Transmission (medicine), Incidence (epidemiology), virus diseases, Non-subtype B, Middle Aged, Infectious Diseases, Female, Adult, Microbiology (medical), Infectious Medicine, medicine.medical_specialty, Biology, Microbiology, Microbiology in the medical area, 03 medical and health sciences, Genetics, medicine, Humans, MSM, Homosexuality, Male, Heterosexuality, Molecular Biology, Ecology, Evolution, Behavior and Systematics, Molecular epidemiology, Public health, BEAST, Heterosexual, Outbreak, Subtype B, Molecular Typing, 030104 developmental biology, Socioeconomic Factors, HIV-1, epidemiology [HIV Infections], Demography
Abstract

The molecular epidemiology of HIV-1 in Iceland has not been described so far. Detailed analyses of the dynamics of HIV-1 can give insights for prevention of virus spread. The objective of the current study was to characterize the genetic diversity and transmission dynamics of HIV-1 in Iceland. Partial HIV-1 pol (1020 bp) sequences were generated from 230 Icelandic samples, representing 77% of all HIV-1 infected individuals reported in the country 1985–2012. Maximum likelihood phylogenies were reconstructed for subtype/CRF assignment and determination of transmission clusters. Timing and demographic growth patterns were determined in BEAST. HIV-1 infection in Iceland was dominated by subtype B (63%, n = 145) followed by subtype C (10%, n = 23), CRF01_AE (10%, n = 22), sub-subtype A1 (7%, n = 15) and CRF02_AG (7%, n = 15). Trend analysis showed an increase in non-B subtypes/CRFs in Iceland over the study period (p = 0.003). The highest proportion of phylogenetic clustering was found among injection drug users (IDUs; 89%), followed by heterosexuals (70%) and men who have sex with men (35%). The time to the most recent common ancestor of the oldest subtype B cluster dated back to 1978 (median estimate, 95% highest posterior density interval: 1974–1981) suggesting an early introduction of HIV-1 into Iceland. A previously reported increase in HIV-1 incidence among IDUs 2009–2011 was revealed to be due to two separate outbreaks. Our study showed that a variety of HIV-1 subtypes and CRFs were prevalent in Iceland 1985–2012, with subtype B being the dominant form both in terms of prevalence and domestic spread. The rapid increase of HIV-1 infections among IDUs following a major economic crisis in Iceland raises questions about casual associations between economic factors, drug use and public health.

Published
2017
Full Text
View/download PDF

21. Marked reduction in the prevalence of hepatitis C viremia among people who inject drugs during 2nd year of the Treatment as Prevention (TraP HepC) program in Iceland

Author

Tyrfingsson, T., primary, Runarsdottir, V., additional, Hansdottir, I., additional, Bergmann, O.M., additional, Björnsson, E.S., additional, Johannsson, B., additional, Sigurdardottir, B., additional, Fridriksdottir, R.H., additional, Löve, A., additional, Löve, T.J., additional, Sigmundsdottir, G., additional, Hernandez, U.B., additional, Heimisdottir, M., additional, Gottfredsson, M., additional, and Olafsson, S., additional

Published
2018
Full Text
View/download PDF

22. Aseptic meningitis outbreak associated with echovirus 4 in Northern Europe in 2013–2014

Author

Arthur Löve, Maija Lappalainen, Teemu Smura, Alexander Lukasev, Susanne Gjeruldsen Dudman, Mia Brytting, Sindy Böttcher, Sofie Midgley, Sabine Diedrich, Thea Kølsen Fischer, Elenor Hauzenberger, Isabelle Schuffenecker, Carita Savolainen-Kopra, Anne J. Jääskeläinen, Olga Ivanova, Bruno Lina, Soile Blomqvist, Pekka Kolehmainen, Petri Susi, HUSLAB, University of Helsinki, Helsinki University Hospital Area, Department of Virology, Clinicum, Medicum, Viral Zoonosis Research Unit, University of Helsinki, HUSLAB, University of Helsinki, Department of Virology, and University of Helsinki, Medicum

Subjects
0301 basic medicine, Echovirus, Picornavirus, SAMPLES, Northern Europe, medicine.disease_cause, Disease Outbreaks, 0302 clinical medicine, Germany, PICORNAVIRUS, Meningitis, Aseptic, 030212 general & internal medicine, Diagnostic screening, Finland, Phylogeny, 11832 Microbiology and virology, biology, Norway, Human parechovirus, ENTEROVIRUSES, Aseptic meningitis, Enterovirus B, Human, 3. Good health, Europe, Infectious Diseases, Adolescent, 030106 microbiology, Echovirus Infections, Viremia, TYPE-3, Young Adult, 03 medical and health sciences, CEREBROSPINAL-FLUID, Virology, medicine, Humans, Sweden, IDENTIFICATION, HUMAN PARECHOVIRUS INFECTIONS, SPAIN, Outbreak, biology.organism_classification, medicine.disease, Central nervous system, Parechovirus, Echovirus 4, 3111 Biomedicine
Abstract

Picornaviruses (family Picornaviridae) are small, nonenveloped, positive-sense, single-stranded RNA viruses. The members of this family are currently classified into 47 genera and 110 species. Of picornaviruses, entero-and parechoviruses are associated with aseptic meningitis. They are transmitted via fecal-oral and respiratory routes, and occasionally, these viruses may cause a brief viremia and gain access to central nervous system (CNS). During the diagnostic screening of entero-and parechovirus types in Finland in year 2013-14, we detected a cluster of echovirus 4 (E4) infections in young adults and adolescents. As E4 is infrequently detected in Finland, we contacted several Northern and Central European laboratories that conduct routine surveillance for enteroviruses and, for those who have had E4 cases, we send a query for E4 sequences and data. Here we report CNS infections caused by E4 in Finland, Sweden, Norway, Denmark, Iceland and Germany in 2013 and 2014, and show that the E4 detected in these countries form a single lineage. In contrast, E4 strains circulating in these countries preceding the year 2013, and those circulating elsewhere in Europe during 2013-2014, formed several independent clusters.

Published
2020
Full Text
View/download PDF

23. THU-412-Iceland may already have reached the WHO 2030 targets for diagnosis and treatment of hepatitis C virus infection: Results from the treatment as prevention for hepatitis C (Trap HepC) program

Author

Ragnheidur H Fridriksdottir, Gudrun Sigmundsdottir, Birgir Johannsson, Ingunn Hansdottir, Einar Bjornsson, Ubaldo Benitez Hernandez, Ottar M. Bergmann, Bryndis Sigurdardottir, Magnus Gottfredsson, Arthur Löve, Thorvardur Jon Love, Thorarinn Tyrfingsson, Sigurdur Olafsson, Maria Heimisdottir, Kamilla S Josefsdottir, and Valgerdur Runarsdottir

Subjects
Trap (computing), Hepatology, business.industry, Hepatitis C virus, Medicine, Hepatitis C, business, medicine.disease, medicine.disease_cause, Treatment as prevention, Virology
Published
2019
Full Text
View/download PDF

24. PS-072-Is homelessness the biggest hurdle to treatment success in the management of HCV in the era of direct acting antivirals? Results from the TraP HepC nationwide treatment initiative in Iceland

Author

Gottfredsson, Magnús, primary, Love, Thorvardur, additional, Fridriksdottir, Ragnheidur H., additional, Tyrfingsson, Thorarinn, additional, Runarsdottir, Valgerdur, additional, Hansdottir, Ingunn, additional, Bergmann, Ottar M., additional, Bjornsson, Einar S., additional, Johannsson, Birgir, additional, Sigurdardottir, Bryndis, additional, Löve, Arthur, additional, Sigmundsdottir, Gudrun, additional, Josefsdottir, Kamilla, additional, Hernandez, Ubaldo B., additional, Heimisdottir, Maria, additional, and Olafsson, Sigurdur, additional

Published
2019
Full Text
View/download PDF

25. PS-072-Is homelessness the biggest hurdle to treatment success in the management of HCV in the era of direct acting antivirals? Results from the TraP HepC nationwide treatment initiative in Iceland

Author

Kamilla S Josefsdottir, Sigurdur Olafsson, Bryndis Sigurdardottir, Arthur Löve, Ottar M. Bergmann, Einar Bjornsson, Magnus Gottfredsson, Ragnheidur H Fridriksdottir, Ubaldo Benitez Hernandez, Thorvardur Jon Love, Valgerdur Runarsdottir, Thorarinn Tyrfingsson, Ingunn Hansdottir, Gudrun Sigmundsdottir, Birgir Johannsson, and Maria Heimisdottir

Subjects
Trap (computing), medicine.medical_specialty, Treatment success, Hepatology, business.industry, medicine, Intensive care medicine, business, DIRECT ACTING ANTIVIRALS
Published
2019
Full Text
View/download PDF

27. Multi-year inter-laboratory exercises for the analysis of illicit drugs and metabolites in wastewater: Development of a quality control system

Author

van Nuijs, Alexander L.N., primary, Lai, Foon Yin, additional, Been, Frederic, additional, Andres-Costa, Maria Jesus, additional, Barron, Leon, additional, Baz-Lomba, Jose Antonio, additional, Berset, Jean-Daniel, additional, Benaglia, Lisa, additional, Bijlsma, Lubertus, additional, Burgard, Dan, additional, Castiglioni, Sara, additional, Christophoridis, Christophoros, additional, Covaci, Adrian, additional, de Voogt, Pim, additional, Emke, Erik, additional, Fatta-Kassinos, Despo, additional, Fick, Jerker, additional, Hernandez, Felix, additional, Gerber, Cobus, additional, González-Mariño, Iria, additional, Grabic, Roman, additional, Gunnar, Teemu, additional, Kannan, Kurunthachalam, additional, Karolak, Sara, additional, Kasprzyk-Hordern, Barbara, additional, Kokot, Zenon, additional, Krizman-Matasic, Ivona, additional, Li, Angela, additional, Li, Xiqing, additional, Löve, Arndís S.C., additional, Lopez de Alda, Miren, additional, McCall, Ann-Kathrin, additional, Meyer, Markus R., additional, Oberacher, Herbert, additional, O'Brien, Jake, additional, Quintana, Jose Benito, additional, Reid, Malcolm, additional, Schneider, Serge, additional, Simoes, Susana Sadler, additional, Thomaidis, Nikolaos S., additional, Thomas, Kevin, additional, Yargeau, Viviane, additional, and Ort, Christoph, additional

Published
2018
Full Text
View/download PDF

28. Treatment as prevention for hepatitis C in Iceland (TRAP HEP C). A real-world experience from a nationwide elimination program using direct acting antiviral agents

Author

Olafsson, S., primary, Tyrfingsson, T., additional, Runarsdottir, V., additional, Bergmann, O.M., additional, Björnsson, E.S., additional, Johannsson, B., additional, Sigurdardottir, B., additional, Fridriksdottir, R.H., additional, Löve, A., additional, Löve, T.J., additional, Sigmundsdottir, G., additional, Heimisdottir, M., additional, and Gottfredsson, M., additional

Published
2017
Full Text
View/download PDF

29. Marked reduction in the prevalence of hepatitis C viremia among people who inject drugs during 2nd year of the Treatment as Prevention (TraP HepC) program in Iceland

Author

Einar Bjornsson, Gudrun Sigmundsdottir, Bryndis Sigurdardottir, Ubaldo Benitez Hernandez, Birgir Johannsson, Magnus Gottfredsson, Arthur Löve, Ingunn Hansdottir, Thorvardur Jon Love, Maria Heimisdottir, Thorarinn Tyrfingsson, S. Olafsson, Valgerdur Runarsdottir, Ottar M. Bergmann, and Run Fridriksdottir

Subjects
medicine.medical_specialty, Hepatology, business.industry, Viremia, Hepatitis C, Treatment as prevention, medicine.disease, Gastroenterology, Trap (computing), 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, 030211 gastroenterology & hepatology, business
Published
2018
Full Text
View/download PDF

31. Improving wastewater-based epidemiology to estimate cannabis use: focus on the initial aspects of the analytical procedure

Author

Causanilles, Ana, primary, Baz-Lomba, Jose Antonio, additional, Burgard, Daniel A., additional, Emke, Erik, additional, González-Mariño, Iria, additional, Krizman-Matasic, Ivona, additional, Li, Angela, additional, Löve, Arndís S.C., additional, McCall, Ann Kathrin, additional, Montes, Rosa, additional, van Nuijs, Alexander L.N., additional, Ort, Christoph, additional, Quintana, José B., additional, Senta, Ivan, additional, Terzic, Senka, additional, Hernandez, Félix, additional, de Voogt, Pim, additional, and Bijlsma, Lubertus, additional

Published
2017
Full Text
View/download PDF

37. Sa1565 Prevalence of Hepatitis E Among Patients Suspected of Drug-Induced Liver Injury, Pig Farm Workers and in the General Population of Iceland

Author

Sigurdur Olafsson, Arthur Löve, Thora Björg Björnsdottir, and Einar Bjornsson

Subjects
Drug, Liver injury, medicine.medical_specialty, education.field_of_study, Hepatology, business.industry, media_common.quotation_subject, Population, Gastroenterology, medicine.disease, Hepatitis E, Surgery, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, Farm workers, 030211 gastroenterology & hepatology, education, business, media_common
Published
2016
Full Text
View/download PDF

44. Measles virus-induced hippocampal neurodegeneration in the mouse: A novel, subacute model for testing neuroprotective agents

Author

Robert Schwarcz, Arthur Löve, Krister Kristensson, and Tommy B. Andersson

Subjects
Neurotoxins, Encephalopathy, Excitotoxicity, Hamster, Pharmacology, Hippocampal formation, medicine.disease_cause, Hippocampus, Receptors, N-Methyl-D-Aspartate, Neuroprotection, Measles virus, Mice, medicine, Animals, Mice, Inbred BALB C, biology, business.industry, General Neuroscience, Neurodegeneration, medicine.disease, biology.organism_classification, Dizocilpine, Disease Models, Animal, Anesthesia, Nerve Degeneration, Female, Dizocilpine Maleate, business, Measles, medicine.drug
Abstract

The hamster neurotropic (HNT) strain of measles virus causes non-inflammatory encephalopathy in Balb/c mice, associated with neurodegeneration in hippocampal CA1 and CA3 regions. This loss of pyramidal cells can be prevented by twice daily systemic treatment with 1 mg/kg dizocilpine (5-methyl-10,11-dihydro-5H-dibenzo(a,d)cyclo-hepten-5,10-imine maleate; MK-801) for 7 days. By varying the MK-801 treatment protocol, we now found that drug administration during the last 4 days prior to sacrifice (i.e. days 4–7 post inoculation, p.i.) is essential for neuroprotection. In contrast, MK-801 treatment during the first days (days 0–4 p.i.) did not prevent the neuronal necrosis. These data suggest that the concentration of an excitotoxic factor in the mouse brain increases after virus inoculation, reaching toxic levels by days 4–5 p.i. This novel ‘subacute’ mouse model of neurodegeneration therefore constitutes an attractive tool for mechanistic and interventional studies in excitotoxicity research.

Published
1993
Full Text
View/download PDF

46. Virus-reactive and autoreactive T cells are accumulated in cerebrospinal fluid in multiple sclerosis

Author

Zhengyu Wang, Sten Fredrikson, Hans Link, Jia-Bin Sun, Arthur Löve, Zhenyi Xu, and Tomas Olsson

Subjects
Adult, Male, Proteolipid protein 1, Adolescent, T-Lymphocytes, T cell, Immunology, Autoimmunity, Mumps virus, medicine.disease_cause, Myelin oligodendrocyte glycoprotein, Measles virus, Epitopes, Myelin, Antigen, medicine, Humans, Immunology and Allergy, Antigens, Cerebrospinal Fluid, biology, Headache, Middle Aged, biology.organism_classification, Myelin basic protein, Myelin-Associated Glycoprotein, medicine.anatomical_structure, nervous system, Neurology, Viruses, biology.protein, Female, Neurology (clinical), Nervous System Diseases, Myelin Proteins, Muscle Contraction
Abstract

Elevated numbers of B cells--plasma cells secreting antibodies to measles and mumps virus, and to myelin associated glycoprotein (MAG), one of several putative myelin autoantigens--have previously been reported in cerebrospinal fluid (CSF) from patients with multiple sclerosis (MS), while it is unknown if corresponding T cell reactivities occur. We have defined the T cell reactivities to measles and mumps virus and to MAG in an immunospot assay which is based on the detection of secretion of interferon-gamma (IFN-gamma) by single cells upon stimulation with specific antigen in short term cultures. Patients with MS had higher numbers of MAG-reactive T cells in blood compared to controls, while no differences were observed for measles or mumps virus-reactive T cells. In CSF, elevated numbers of MAG-reactive T cells and also of measles- and mumps-reactive T cells were found in patients with MS compared to other neurological diseases. A strong accumulation of antigen-reactive T cells was observed in the MS patients' CSF compared to blood. The magnitude of these T cell reactivities did not correlate with clinical MS variables. The T cell repertoire in MS thus includes, besides myelin basic protein, proteolipid protein and myelin oligodendrocyte glycoprotein, also MAG and, in addition, measles and mumps virus. It is not clear whether these T cell reactivities accumulated in the CSF have importance for the pathogenesis of MS or reflect phenomena secondary to myelin damage, or result from both these alternatives.

Published
1992
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results